sb 203580 has been researched along with alpha-aminopyridine in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (alpha-aminopyridine) | Trials (alpha-aminopyridine) | Recent Studies (post-2010) (alpha-aminopyridine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 5,813 | 460 | 3,246 |
| Protein | Taxonomy | sb 203580 (IC50) | alpha-aminopyridine (IC50) |
|---|---|---|---|
| Botulinum neurotoxin type A | Clostridium botulinum | 1.8 | |
| Nitric oxide synthase, endothelial | Homo sapiens (human) | 2.8 | |
| Nitric oxide synthase, brain | Homo sapiens (human) | 6 | |
| Nitric oxide synthase, brain | Rattus norvegicus (Norway rat) | 9 | |
| Nitric oxide synthase, inducible | Homo sapiens (human) | 1.9 | |
| Phosphatidylinositol 4-kinase alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-beta | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase type 2-alpha | Homo sapiens (human) | 7.1 | |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | 7.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer, SA; Ruff, KJ; Zimmermann, W | 1 |
| Chang, A; Cheng, D; Huang, S; Liu, AT; Sun, P; Tan, X; Wang, G; Wang, J; Wang, Q; Wu, D; Xiang, R; Yang, S; Zhao, S | 1 |
2 other study(ies) available for sb 203580 and alpha-aminopyridine
| Article | Year |
|---|---|
Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.
Topics: Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytokines; Humans; Imidazoles; In Vitro Techniques; Interleukin-1; Isoenzymes; Models, Molecular; Molecular Conformation; p38 Mitogen-Activated Protein Kinases; Pyridines; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2004 |
Her2 promotes early dissemination of breast cancer by suppressing the p38-MK2-Hsp27 pathway that is targetable by Wip1 inhibition.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dipeptides; Female; Heat-Shock Proteins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Neoplasm Metastasis; Phosphorylation; Protein Phosphatase 2C; Protein Serine-Threonine Kinases; Pyridines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2020 |